These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 1981321)

  • 1. The effects of beta-adrenoceptor antagonists and levomepromazine on the metabolic ratio of debrisoquine.
    Kallio J; Huupponen R; Seppälä M; Säkö E; Iisalo E
    Br J Clin Pharmacol; 1990 Oct; 30(4):638-43. PubMed ID: 1981321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of levomepromazine and metabolites on debrisoquine hydroxylation in the rat.
    Hals PA; Dahl SG
    Pharmacol Toxicol; 1994 Nov; 75(5):255-60. PubMed ID: 7870695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defective metabolism of metoprolol in poor hydroxylators of debrisoquine.
    Lennard MS; Silas JH; Freestone S; Trevethick J
    Br J Clin Pharmacol; 1982 Aug; 14(2):301-3. PubMed ID: 6125207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.
    Lennard MS; Tucker GT; Woods HF
    Clin Pharmacokinet; 1986; 11(1):1-17. PubMed ID: 2868819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio.
    Kallio J; Lindberg R; Huupponen R; Iisalo E
    Br J Clin Pharmacol; 1988 Dec; 26(6):791-5. PubMed ID: 3242585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol.
    Lennard MS; Tucker GT; Silas JH; Woods HF
    Xenobiotica; 1986 May; 16(5):435-47. PubMed ID: 2874665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics.
    Lewis RV; Lennard MS; Jackson PR; Tucker GT; Ramsay LE; Woods HF
    Br J Clin Pharmacol; 1985 Mar; 19(3):329-33. PubMed ID: 2859048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Debrisoquine oxidation phenotype during neuroleptic monotherapy.
    Spina E; Martines C; Caputi AP; Cobaleda J; Piñas B; Carrillo JA; Benitez J
    Eur J Clin Pharmacol; 1991; 41(5):467-70. PubMed ID: 1684751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory effects of neuroleptics on debrisoquine oxidation in man.
    Syvälahti EK; Lindberg R; Kallio J; De Vocht M
    Br J Clin Pharmacol; 1986 Jul; 22(1):89-92. PubMed ID: 2874826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphic metabolism of beta-adrenoceptor antagonists.
    Silas JH; Lennard MS; Tucker GT; Ramsay LE; Woods HF
    Br J Clin Pharmacol; 1984; 17 Suppl 1(Suppl 1):11S-19S. PubMed ID: 6146335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. d-Propoxyphene is a potent inhibitor of debrisoquine, but not S-mephenytoin 4-hydroxylation in vivo.
    Sanz EJ; Bertilsson L
    Ther Drug Monit; 1990 May; 12(3):297-9. PubMed ID: 2349617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies.
    McGourty JC; Silas JH; Lennard MS; Tucker GT; Woods HF
    Br J Clin Pharmacol; 1985 Dec; 20(6):555-66. PubMed ID: 2868742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The oral clearance and beta-adrenoceptor antagonist activity of propranolol after single dose are not related to debrisoquine oxidation phenotype.
    Lennard MS; Jackson PR; Freestone S; Ramsay LE; Tucker GT; Woods HF
    Br J Clin Pharmacol; 1984; 17 Suppl 1(Suppl 1):106S-107S. PubMed ID: 6146334
    [No Abstract]   [Full Text] [Related]  

  • 14. Influence of debrisoquine oxidation phenotype on exercise tolerance and subjective fatigue after metoprolol and atenolol in healthy subjects.
    Lewis RV; Ramsay LE; Jackson PR; Yeo WW; Lennard MS; Tucker GT
    Br J Clin Pharmacol; 1991 Apr; 31(4):391-8. PubMed ID: 2049246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metoprolol alpha-hydroxylation polymorphism in the San Bushmen of southern Africa.
    Sommers DK; Moncrieff J; Avenant J
    Hum Toxicol; 1989 Jan; 8(1):39-43. PubMed ID: 2714809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of timolol on intraocular pressure and exercise heart rate in poor and extensive debrisoquine metabolizers.
    al-Sereiti MR; Edeki T; Lledo P; Turner P
    Int J Clin Pharmacol Res; 1990; 10(6):339-45. PubMed ID: 2099359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralol.
    Dayer P; Balant L; Kupfer A; Striberni R; Leemann T
    Eur J Clin Pharmacol; 1985; 28(3):317-20. PubMed ID: 2861095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.
    Zhen Y; Slanar O; Krausz KW; Chen C; Slavík J; McPhail KL; Zabriskie TM; Perlík F; Gonzalez FJ; Idle JR
    Drug Metab Dispos; 2006 Sep; 34(9):1563-74. PubMed ID: 16782768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation.
    Meier PJ; Mueller HK; Dick B; Meyer UA
    Gastroenterology; 1983 Sep; 85(3):682-92. PubMed ID: 6603386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Debrisoquine hydroxylation phenotyping in geriatric psychopharmacology.
    Pollock BG; Perel JM; Altieri LP; Kirshner M; Fasiczka AL; Houck PR; Reynolds CF
    Psychopharmacol Bull; 1992; 28(2):163-8. PubMed ID: 1513919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.